This week in drug discovery (22-26 April) 

News round-up for 22-26 April by DDW Digital Content Editor Diana Spencer.

The leading news story this week has been the launch of a new clinical trial in the UK for a melanoma personalised mRNA cancer vaccine, but there have been a number of other interesting developments in cancer drug discovery. These include the detection of new targets for skin cancer treatment, the benefits of vitamin D for cancer prevention, an extended approval in the EU for a CAR-T myeloma therapy and the discovery of an unusual source of targeted treatments.

The top stories:

Discovery reveals two potential drug targets against skin cancer

Scientists have discovered how skin cancer cells shapeshift based on their environment – enabling them to spread through the body and cause a metastatic cancer.

Rice bran nanoparticles show promise as targeted cancer therapy

Researchers have discovered that nanoparticles derived from rice bran are both effective and safe for the treatment of cancer.

EC expands use of BCMA-targeted CAR-T therapy

The European Commission (EC) has approved a Type II variation for Carvykti (ciltacabtagene autoleucel; cilta-cel) for the treatment of adult patients with relapsed and refractory multiple myeloma (RRMM).

Vitamin D boosts ‘good’ bacteria and improves immunity to cancer

Researchers have found that vitamin D encourages the growth of a type of gut bacteria in mice which improves immunity to cancer.

“Game-changing” personalised cancer vaccine enters UK clinical trials

A clinical trial of a personalised mRNA cancer vaccine for melanoma patients has been launched in the UK.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free